

MICHELE PALUMBO

Date of Birth: 01/09/1994

Nationality: Italian

Gender: Male

WORK EXPERIENCE

Hematologist

SC Ematologia 1 – Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

16/02/2025 – Present

- Diagnosis, management, and treatment of plasma cell malignancies.
- Clinical activity in the Hematology Multiple Myeloma and Plasma Cells Disorders Day Unit.

Medical Doctor, Hematology Resident

Department of Molecular Medicine, University of Pavia

28/12/2020 – 22/01/2025

- Diagnosis, management, and treatment of hematological malignancies.
- Experience in stem cell transplantation and CAR-T therapies.
- Clinical research participation in multiple international trials.

Additional Clinical Experience:

- Hemostasis and thrombosis clinic, SC Medicina Generale 3, IRCCS Policlinico San Matteo, Pavia: diagnosis, management, and treatment of hemorrhagic diseases and anticoagulation therapy (July 2021).
- Hematology division, SC Ematologia, ASST Sette Laghi, Varese: diagnosis, management, and treatment of hematological malignancies and autologous stem cell transplantation (July 2021 - October 2021).
- Stem Cell Transplantation & Cellular Therapy Unit, SC Ematologia, IRCCS Policlinico San Matteo, Pavia: management of autologous and allogeneic stem cell transplant and CAR-T therapies (July 2022 – February 2023).
- Oncohematology division, Ospedale Maggiore di Lodi: diagnosis, management, and treatment of hematological malignancies (February 2023 – June 2023).

EDUCATION & TRAINING

Hematology Residency – Hematology Specialist

University of Pavia, Italy

25/01/2021 – 22/01/2025

Medical Degree – Doctor of Medicine

University of Molise, Italy

28/10/2013 – 31/10/2019

High School Diploma

Istituto di Istruzione Superiore E. Medi, San Bartolomeo In Galdo, Italy

01/09/2008 – 01/07/2013

RESEARCH & PUBLICATIONS

- Mangiacavalli S. et al. *Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.* Haematologica, 2022.
- Mangiacavalli S. et al. *Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS.* Am J Hematol, 2025.
- Bellofiore C. et al. *A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.* Hematol Oncol, 2024.
- Cavallaro G. et al. *Impact of the Addition of Daratumumab to Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection.* Blood, 2023.

CLINICAL RESEARCH EXPERIENCE

Clinical Research as Sub-investigator:

- **MajesTEC-7:** A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant.
- **MajesTEC-4 (EMN30):** A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
- **ERASMM:** A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma.
- **MONUMENTAL-6:** A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (TalPom), Talquetamab in Combination with Teclistamab (TalTec), and Elotuzumab (IV), Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib (SC), and Dexamethasone (PVD) in Participants with Relapsed or Refractory Myeloma who Have Received at Least 1-4 Prior Line of Therapy.
- **MonumenTAL-3:** Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy.

- **EMN33 (TAURUS):** Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT).
- **LINKER-MM3:** A Phase 3, Open-label, Randomized Study of Linvoseltamab Versus Elotuzumab, Pomalidomide, and Dexamethasone (EPd) in Relapsed/Refractory Multiple Myeloma (RRMM).
- **CA057-003:** A Study to Evaluate Safety, Drug Levels, and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma.
- **EMN26:** Phase II Study of Ibrandomide (CC220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma.
- **EMN36:** EMN Prospective Sample Collection Project.
- **EMN-COVID:** COVID-19 Infection in Multiple Myeloma Patients: A European Prospective and Retrospective Observational Study.
- **The IRAKLIA Study:** A Randomized, Phase 3, Open-label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination with Pomalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
- **DREAMM-8:** A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin-Pd Vs Pvd in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- **DREAMM-3:** A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin Monotherapy Compared with Pom/Dex in Participants with RRMM.
- **The Perseus Study:** A Phase 3 Study Comparing D-VRd vs VRd in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-Dose Therapy.
- **IsKia trial-EMN24:** Phase III Study of Isa-KRd Versus KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
- **EMN18:** A Multicenter, Open-label, Randomized Phase II Study Comparing Dara-VCD Versus VTD as Pre-Transplant Induction and Post-Transplant Consolidation, Both Followed by a Maintenance Phase with Ixazomib Alone or in Combination with Daratumumab, in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
- **MaRK Study:** A Study to Evaluate Minimal Residual Disease (MRD) Status, Measured by NGS, in RRMM Patients Treated with KRd in a Real-Life Setting.

- **MoMMent Study:** A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma.
- **LocoMMotion Study:** A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma.
- **A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant.**

DIGITAL SKILLS

- Microsoft Office Suite (Word, Excel, PowerPoint, Outlook)
- Google Docs
- Zoom

LANGUAGE SKILLS

- **Italian** (Native)
- **English** (C1 Listening & Speaking, C2 Reading & Writing)

Contact Information & References Available Upon Request